Change of Board of Directors and Management Committee

board of directors

Basel, December 12, 2022 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced at its December meeting that the Board of Directors of Roche Holding Ltd made the following at its Annual General Meeting of Shareholders on March 14, 2023: announced its approval to propose changes to :

As previously announced in July 2022, Christoph Franz has decided not to seek re-election as Chairman. The Board of Directors has proposed Severin Schwan as the new Chairman at the 2023 Annual General Meeting and has appointed Thomas Schinekker as the new Roche Group CEO effective March 14, 2023.

proposed by the board of directors. Mark SchneiderCEO of Nestlé SA, and Professor Akiko Iwasaki, Sterling Professor of Immunobiology and Molecular, Cellular and Developmental Biology at Yale University, and Howard Hughes Medical Institute Researcher were elected as new board members at the 2023 Annual Meeting. Christoph Franz: Extraordinary people in business and science elected to the Board of Directors. ”

The following persons are nominated for election to the Board of Directors:

Annette Luther, Executive Secretary, will be appointed as Head of International Government Relations in April 2023.at the same time Per-Olof AttingerCurrently Head of the Office of the Chief Executive Officer (CEO) and Secretary to the Corporate Executive Committee, he will assume the role of Secretary to the Board of Directors.

Management meeting

Bill AndersonRoche Pharmaceuticals, CEO of Roche Pharmaceuticals and member of the Corporate Executive Committee, has decided to pursue non-Roche opportunities effective December 31, 2022. He will hand over the role of CEO of Roche Diagnostics to Matt Sause, as previously announced.

story continues

Severin Schwan: “During his 16-year career at Roche, Bill Anderson has demonstrated exceptional leadership. .”

After joining Genentech in 2006 as senior vice president of the Immunology and Ophthalmology business unit in South San Francisco, CA (SSF), he led the BioOncology business unit. He moved to Basel and in 2013 became Head of Global Product Strategy and Chief Marketing Officer of the Pharmaceuticals business. By 2016, Bill was back in San Francisco to lead Genentech’s North American operations, and shortly thereafter he was named CEO of Genentech. He assumed his current role in 2019. Prior to joining Roche, he began his career in engineering and quickly assumed his leadership role in the business as it expanded its reach in the biotechnology industry. Bill holds an MS in Chemical Engineering from the Massachusetts Institute of Technology and a BS in Chemical Engineering from the University of Texas at Austin.

Silke HernsteinCurrently Global Head of Strategy and Transformation for Roche’s Diagnostics Division, will become Head of Corporate Strategy, Secretary of the Corporate Executive Committee and a member of the expanded Corporate Executive Committee in April 2023.

Thomas Schinecker: “Silke Hörnstein is a strong leader with extensive experience and strategic acumen. I am impressed with how she consistently finds sustainable solutions to complex topics. .”

Silke Hörnstein joined Roche in Penzberg, Germany in 2001 in Procurement before moving directly to Mannheim in 2005 as Director of Procurement. She then took on more and more responsibility in sales operations after she transitioned into product management at Diagnostics. In 2012, she was appointed Diagnostics General Manager for Denmark and she moved to Copenhagen. She was responsible for multiple global programs in Basel in 2015, including the digital transformation of the diagnostics department, before assuming her current role in 2021 across strategy and diagnostic sites. Silke holds a Master of Science in Cellular and Molecular Biology from Ruprecht-Karls University, Heidelberg, Germany, and is conducting additional research in this area at the University of Connecticut, USA.

About Roche
Founded in 1896 in Basel, Switzerland, Roche was one of the first industrial manufacturers of branded pharmaceuticals and has grown to become the world’s largest biotechnology company and a global leader in in vitro diagnostics. The company strives for scientific excellence to discover and develop medicines and diagnostics to improve and save lives around the world. We are pioneers in personalized healthcare and want to further transform the way healthcare is delivered to have an even greater impact. We partner with many stakeholders to combine our strengths in diagnostics and pharmaceuticals with data insights from clinical practice to provide the best possible care for each individual.

For the 13th consecutive year, Roche has been named one of the most sustainable companies in the pharmaceutical industry by the Dow Jones Sustainability Indices, in recognition of its efforts to pursue a long-term perspective in all that it does. The award also reflects our commitment to working with local partners to improve access to healthcare in all the countries in which we operate.

Genentech in the US is a wholly owned subsidiary of the Roche Group. Roche is the largest shareholder of Chugai Pharmaceutical in Japan.

For more information, see: www.roche.com.

All trademarks used or mentioned in this release are protected by law.

Roche Group Media Relations
Phone: +41 61 688 8888 / Email: media.relations@roche.com

accessories